Ahmed B. M. Mehany - Search Results

Year	Number of Results
2017	1
2018	5
2019	10
2020	14
2021	13
2022	15
2023	5
2024	0

1

Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma.

Eissa IH, Ibrahim MK, Metwaly AM, Belal A, Mehany ABM, Abdelhady AA, Elhendawy MA, Radwan MM, ElSohly MA, Mahdy HA. Eissa IH, et al. Among authors: mehany abm. Bioorg Chem. 2021 Feb;107:104532. doi: 10.1016/j.bioorg.2020.104532. Epub 2020 Dec 8. Bioorg Chem. 2021. PMID: 33334586

2

Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.

Bakr RB, Mehany ABM, Abdellatif KRA. Bakr RB, et al. Among authors: mehany abm. Anticancer Agents Med Chem. 2017;17(10):1389-1400. doi: 10.2174/1872211311666170213105004. Anticancer Agents Med Chem. 2017. PMID: 28270084

3

Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors.

Belal A, Abdel Gawad NM, Mehany ABM, Abourehab MAS, Elkady H, Al-Karmalawy AA, Ismael AS. Belal A, et al. Among authors: mehany abm. J Enzyme Inhib Med Chem. 2022 Dec;37(1):1884-1902. doi: 10.1080/14756366.2022.2096019. J Enzyme Inhib Med Chem. 2022. PMID: 35801486 Free PMC article.

4

Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.

El-Adl K, Sakr HM, Yousef RG, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, Abulkhair HS, Eissa IH. El-Adl K, et al. Among authors: mehany abm. Bioorg Chem. 2021 Sep;114:105105. doi: 10.1016/j.bioorg.2021.105105. Epub 2021 Jun 18. Bioorg Chem. 2021. PMID: 34175720

5

Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies.

Yousef RG, Elwan A, Gobaara IMM, Mehany ABM, Eldehna WM, El-Metwally SA, A Alsfouk B, Elkaeed EB, Metwaly AM, Eissa IH. Yousef RG, et al. Among authors: mehany abm. J Enzyme Inhib Med Chem. 2022 Dec;37(1):2206-2222. doi: 10.1080/14756366.2022.2110868. J Enzyme Inhib Med Chem. 2022. PMID: 35980113 Free PMC article.

6

Apoptotic and anti-angiogenic effects of propolis against human bladder cancer: molecular docking and in vitro screening.

Mehany ABM, Belal A, Mohamed AF, Shaaban S, Abdelhamid G. Mehany ABM, et al. Biomarkers. 2022 Mar;27(2):138-150. doi: 10.1080/1354750X.2021.2020903. Epub 2022 Jan 3. Biomarkers. 2022. PMID: 34927500

7

Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation.

Elwan A, Abdallah AE, Mahdy HA, Dahab MA, Taghour MS, Elkaeed EB, Mehany ABM, Nabeeh A, Adel M, Alsfouk AA, Elkady H, Eissa IH. Elwan A, et al. Among authors: mehany abm. Molecules. 2022 Aug 8;27(15):5047. doi: 10.3390/molecules27155047. Molecules. 2022. PMID: 35956997 Free PMC article.

8

Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors.

Abdallah AE, Mabrouk RR, Al Ward MMS, Eissa SI, Elkaeed EB, Mehany ABM, Abo-Saif MA, El-Feky OA, Alesawy MS, El-Zahabi MA. Abdallah AE, et al. Among authors: mehany abm. J Enzyme Inhib Med Chem. 2022 Dec;37(1):573-591. doi: 10.1080/14756366.2021.2017911. J Enzyme Inhib Med Chem. 2022. PMID: 35012403 Free PMC article.

9

Apoptosis: A target for anticancer therapy with novel cyanopyridines.

Ismail MMF, Farrag AM, Harras MF, Ibrahim MH, Mehany ABM. Ismail MMF, et al. Among authors: mehany abm. Bioorg Chem. 2020 Jan;94:103481. doi: 10.1016/j.bioorg.2019.103481. Epub 2019 Dec 5. Bioorg Chem. 2020. PMID: 31837830

10

New quinoxalin-2(1H)-one-derived VEGFR-2 inhibitors: Design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies.

El-Adl K, Sakr HM, Yousef RG, Mehany ABM, Abulkhair HS, Eissa IH. El-Adl K, et al. Among authors: mehany abm. Arch Pharm (Weinheim). 2022 Jul;355(7):e2200048. doi: 10.1002/ardp.202200048. Epub 2022 Apr 18. Arch Pharm (Weinheim). 2022. PMID: 35437829

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

55 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year